Cor Vasa 2021, 63(1):32-39 | DOI: 10.33678/cor.2020.082

Prognostic Value of High Sensitive Troponin T in Patients with Chronic Ischemic Heart Disease Undergoing Percutaneous Coronary Intervention

Halil Aktaş^a, Onur Kaypakli^b, Caglar Ozmen^c, Murat Gul^a, Oguz Yildirim^d, Sinan Inci^a, Ali Deniz^c, Mustafa Demirtas^c

^a Faculty of Medicine, Aksaray University, Aksaray, Turkey

^b Faculty of Medicine, Mustafa Kemal University, Hatay, Turkey

^c Faculty of Medicine, Cukurova University, Adana, Turkey

^d Aksaray State Hospital, Aksaray, Turkey

Objective: Several studies have investigated different cardiac biomarkers as predictors of the prognosis after percutaneous coronary interventions (PCI) in patients with chronic ischemic heart disease; nevertheless, the results of these studies are conflicting. High sensitive troponin T (Hs-TnT) measurement is a novel and sensitive method. The aim of this study was to investigate if Hs-TnT levels are a predictor of major adverse cardiovascular events (MACE) in the first year after a successful elective PCI in patients with stable angina pectoris (SAP).

Material and methods: 100 patients who presented with SAP and underwent successfully elective PCI were included in the study. Patients with elevated troponin I levels (>0.1 ng/mL) before the procedure excluded from the study. Hs-TnT levels were measured before the procedure and at 3-4 hours (h) (early period) and 12-24 hours (late period) after the procedure and Hs-TnT level >14 pg/mL was considered positive. The incidence of MACE during the first year was recorded.

Results: Hs-TnT levels were positive in 36% of the patients in the early period and in 54% of the patients in the late period. The incidence rate of MACE for the first year was significantly higher in the patients with positive Hs-TnT levels in the early period but not the late period (36.1% vs. 15.6%; p = 0.026) and logistic regression analysis yielded an odds ratio of 3.36.

Conclusion: Hs-TnT levels measured 3-4 h after a successful elective PCI in patients with SAP can predict the incidence of MACE within the first year. Nonetheless, these results must be corroborated by other larger studies.

Keywords: Chronic ischemic heart disease, High sensitive troponin T, Major adverse cardiovascular events, Percutaneous coronary intervention, Prognosis

Received: July 27, 2020; Revised: July 27, 2020; Accepted: September 6, 2020; Published: February 25, 2021  Show citation